Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

Launched by UNIVERSITY OF WASHINGTON, THE COLLABORATIVE HEALTH STUDIES COORDINATING CENTER · Oct 21, 2024

Keywords

ClinConnect Summary

The STOP PEDS trial is researching how effective and safe two different antibiotic treatments are for children and teenagers with cystic fibrosis (CF) who are experiencing lung infections. This study aims to help manage these infections, known as pulmonary exacerbations (PEx), both in the short term and over a year. It is currently looking for participants aged 3 to 18 who have been diagnosed with CF and are taking specific CF medications called Highly Effective Modulator Therapies (HEMT) for at least three months.

To participate, children must meet several criteria, including being able to perform certain lung function tests and not having recently taken other antibiotics. If eligible, participants will receive one of the two antibiotic treatments and will be monitored throughout the study period. This trial is a great opportunity for young patients with CF to contribute to important research that could improve care for their condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age
• • 1. For main cohort and non-HEMT cohort: age 6 to \<19 years
• • 2. For preschool cohort: age 3 to \<6 years
• 2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
• • 1. sweat chloride ≥ 60 mEq/liter
• • 2. two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
• • 3. Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study
• • 4. Highly Effective Modulator Therapy
• • 1. For main cohort and preschool cohort: Taking ETI or ivacaftor for at least 3 months at enrollment
• • 2. For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
• • 5. For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry
• • 6. For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations
• • 7. Ability to receive text messages and access the internet
• Exclusion Criteria:
• • 1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
• • 2. Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
• • 3. Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
• • 4. History of solid organ transplant
• • 5. History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
• • 6. Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
• • 7. Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
• • 8. Treatment with chronic oral antibiotics other than azithromycin at enrollment
• • 9. Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment